A Few Thoughts As a quick disclaimer, these opinions are my own and I have no connections with GAP. I also have not bought any GAP shares in the past 6 months, and Bryden did buy some of my shares from me back at the end of March.
I think the tides are likely finally starting to turn for the company and their shareholders. If the drug performs (and that is definitely a big if), the share price will do well from here given that there is no longer any need for private placements to move their lead drug forward. So often that was the achilles' heel, as the company would get a little momentum going and then the share price would get hammered by another private placement. In this business testing is not cheap, and the company was burning close to $200,000/month. Management fees (Stormont), were also quite high, although in the end they were the only ones willing to foot the bill going forward when push came to shove.
Bob says it best in summing up the current state of affairs at GAP:
""This is an extremely beneficial transaction to PharmaGap and its shareholders. Our shareholders will require no further dilution to complete the clinical trial program for our lead cancer drug. The PharmaGap pipeline program, which we believe will have significant potential value, will be supported and enhanced by revenues from Clinical Value Corp. The performance of the drug in clinical trials will determine whether or not value will be achieved, and the cost will be assumed by Clinical Value Corp. and not the PharmaGap shareholders."
I can't say I have always agreed with Bob, but I do agree with that statement.
I think there is a good chance that the company will get the results they are looking for in the next batch of testing, and that will move them towards where they want to be. If that happens, and given no further dilution for their lead drug, I think the share price will do well from here.
At the end of the day take my opinion for what it's worth. I have been wrong on this one all the way down, and own up to that.